AZN

p11,637.14

▲+0.41%

wb_incandescent Backtest

Stock

Astrazeneca Plc Ord Shs $0.25

Official Company Name: AstraZeneca plc

Stock Symbol: AZN

Stock Market: London Stock Exchange - LSE

Currency: Penny sterling - GBX

business AstraZeneca Company Profile

AZN Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▲+13.49%

file_download

Daily closing prices, with moving averages and volumes - Penny sterling (GBX)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

AstraZeneca PLC is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. AstraZeneca develops, manufactures, and sells pharmaceuticals and biotechnology products to treat major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

business AstraZeneca Company Profile

AZN Stock Data

Open p11,546.00
High p11,778.00
Low p11,534.00
Close p11,637.14
Volume 714,708
Previous Close p11,590.00
1-Day Change 47.14
1-Year Change 1383.14
Average Daily Volume 2,351,736
52-Week High p13,276.00
52-Week Low p9,725.00

Ratios as of Jan. 25, 2025

Beta 0.18
Trailing PE 31.91
Forward PE 15.07
Financial Reports & Statistics

AZN Stock References

warning

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.